Treatment
Relatlimab clinical trials
We’re tracking 30 recruiting studies that include Relatlimab, each written for real people, not researchers, below.
Recruiting studies
- NCT05704647RecruitingPhase 2
Nivolumab plus relatlimab for melanoma in the brain
This Phase 2 study tests whether nivolumab plus relatlimab can shrink or control melanoma that has spread to the brain. It may help by boosting the immune system to attack the cancer, including melanoma in brain areas that can’t be treated with prior focused radiation.
Houston, TexasAges 18 years+ - NCT06999980RecruitingPhase 2
NEOadjuvant Ipi Nivo Rela for Melanoma
This trial tests a combination of three immunotherapy drugs (ipilimumab, relatlimab, and nivolumab) given before surgery to people with melanoma that can be completely removed. The goal is to see if this treatment shrinks the tumor and improves outcomes.
Wollstonecraft, New South WalesAges 18 years+ - NCT06683755RecruitingPhase 1/Phase 2
A study of three immunotherapy drugs for advanced melanoma
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
Houston, TexasAges 18 years+ - NCT07504796RecruitingPhase 2
Adding ipilimumab to standard melanoma therapy based on ctDNA
This trial tests whether adding a second immunotherapy drug (ipilimumab) to the standard first-line combo of nivolumab and relatlimab improves outcomes for advanced melanoma. It uses a blood test (ctDNA) to decide who gets the extra drug.
New York, New YorkAges 18 years+ - NCT06816927RecruitingPhase 2
Immunotherapy trial for glioblastoma with nivolumab and relatlimab
This trial tests whether two immunotherapy drugs, nivolumab and relatlimab, can help treat glioblastoma (GBM), a type of brain tumor. It is for people newly diagnosed or who haven't had radiation or chemotherapy yet and are scheduled for surgery.
New York, New YorkAges 18 years+ - NCT06561386RecruitingPhase 3
Testing a new drug combo for advanced lung cancer
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
Mobile, AlabamaAges 18 years+ - NCT06288191RecruitingPhase 2
Nivolumab and relatlimab before surgery for skin cancer
This trial tests if two immunotherapy drugs, nivolumab and relatlimab, given before surgery can help shrink a type of skin cancer called cutaneous squamous cell carcinoma. It's for people whose cancer can be removed with surgery.
Wollstonecraft, New South WalesAges 18 years+ - NCT03521830RecruitingPhase 2
Nivolumab and other immunotherapy for advanced basal cell skin cancer
This study tests how well the immunotherapy medicine nivolumab works—either by itself or combined with other immune-boosting drugs—for people with advanced basal cell carcinoma that can’t be removed by surgery or has spread. It’s also looking at what to do if the cancer grows again after an earlier immunotherapy.
Baltimore, MarylandAges 18 years+ - NCT03899155RecruitingPhase 2
Study for continuing or restarting cancer treatment that worked before
This trial lets people who were already in a related “parent” study either keep taking treatment or restart it after it had stopped working for a while. It’s meant for people who previously had a meaningful response and may still benefit from continued treatment.
Huntsville, AlabamaAges 18 years+ - NCT06029270RecruitingPhase 2
Adding relatlimab to standard immunotherapy for nasopharyngeal cancer
This trial tests whether adding a new drug called relatlimab to the usual immunotherapy (nivolumab) helps people with nasopharyngeal cancer that has returned or spread. You will get standard chemotherapy plus nivolumab first, then if it works, you may be randomly assigned to get nivolumab alone or with relatlimab.
Dublin, CaliforniaAges 18 years+ - NCT06151236RecruitingPhase 2
Nivolumab and relatlimab before surgery for Merkel cell cancer
This trial tests a combination of two immunotherapy drugs, nivolumab and relatlimab, before surgery for Merkel cell carcinoma that can be removed. The goal is to see if this treatment shrinks the tumor and improves outcomes.
Wollstonecraft, New South WalesAges 18 years+ - NCT06624475RecruitingPhase 2
New immunotherapy before surgery for high-risk basal cell cancer
This trial tests if giving a combination of two immunotherapy drugs (nivolumab and relatlimab) before surgery works better than one drug alone for people with large or high-risk basal cell skin cancer that needs surgery. The goal is to shrink the cancer and make surgery easier.
Irvine, CaliforniaAges 18 years+ - NCT06708949RecruitingPhase 2
Immunotherapy combo for advanced kidney cancer
This trial compares two immunotherapy combinations—nivolumab/relatlimab/ipilimumab vs. nivolumab/ipilimumab—as first treatment for advanced kidney cancer with clear cell features. It aims to see which combo works better for people who haven't had prior therapy.
Boston, MassachusettsAges 18 years+ - NCT06712927RecruitingPhase 2
Three-drug immunotherapy for melanoma brain metastases
This trial tests a combination of three immunotherapy drugs (relatlimab, nivolumab, and ipilimumab) for people with melanoma that has spread to the brain. It aims to see if this treatment can shrink brain tumors and improve outcomes.
Palo Alto, CaliforniaAges 18 years+ - NCT06246916RecruitingPhase 3
Testing a new immunotherapy combo for advanced melanoma
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
Chandler, ArizonaAges 18 years+ - NCT06743126RecruitingPhase 3
IMA203 vs standard treatment for advanced skin cancer
This trial tests a new cell therapy called IMA203 against standard treatments for people with advanced melanoma (a type of skin cancer) that has spread or can't be removed. It may be an option if you have already tried certain treatments and your cancer has a specific cell marker (HLA-A*02:01).
Phoenix, ArizonaAges 18 years+ - NCT05987241RecruitingPhase 2/Phase 3
Using a blood test to guide immunotherapy after bladder/kidney cancer surgery
This study tests whether a blood test that detects tumor DNA can help guide the use of immunotherapy (nivolumab with or without relatlimab) after surgery for urothelial cancer. The goal is to see if starting immunotherapy based on the blood test results can prevent the cancer from coming back.
Phoenix, ArizonaAges 18 years+ - NCT06264180RecruitingPhase 3
Viral therapy and nivolumab for advanced melanoma
This trial tests a combination of an investigational viral therapy (VO) and the immunotherapy nivolumab for people with advanced melanoma that has stopped responding to previous anti-PD-1 and anti-CTLA-4 treatments. The goal is to see if this combination works better than other standard treatments your doctor might choose.
Gilbert, ArizonaAges 12 years+ - NCT04204837RecruitingPhase 2
Nivolumab for advanced skin squamous cell cancer
This trial studies nivolumab, an immune therapy, for skin squamous cell cancer that can’t be cured with surgery or radiation. It aims to see how well the treatment shrinks tumors and helps people live longer or longer without cancer growth.
GrazAges 18 years+ - NCT06112314RecruitingPhase 3
New immunotherapy combo for advanced melanoma (first treatment)
This trial tests a new immunotherapy drug (IMC-F106C) combined with standard treatments against the usual nivolumab-based therapy for people with advanced melanoma who have not been treated before. It's for people who carry a specific immune system marker (HLA-A*02:01) and are in fairly good health.
Tucson, ArizonaAges 18 years+ - NCT07223411Recruiting
Opdualag vs. cemiplimab/fianlimab for melanoma
This trial compares two treatments for advanced melanoma that cannot be removed with surgery or has spread. It studies how these treatments affect the immune response in tumors and blood, and requires extra biopsies and blood draws.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Phoenix, ArizonaAges 18 years+ - NCT07492680RecruitingPhase 2
Study of BMS-986504 for solid tumors with MTAP deletion
This trial tests an experimental drug called BMS-986504, given alone or with other drugs, for people with advanced solid tumors that have a specific genetic change called a homozygous MTAP deletion. It may be an option if standard treatments are no longer working or aren't available.
San Francisco, CaliforniaAges 18 years+ - NCT07281924RecruitingPhase 1/Phase 2
Combination Treatment for Melanoma Spread to Liver
This trial tests a combination of liver-directed chemotherapy (HEPZATO KIT) with a new immunotherapy called Opdualag for people whose melanoma has spread to the liver and who have not had many prior treatments.
Madison, WisconsinAges 18 years+
What Relatlimab is being studied for
Conditions with recruiting Relatlimab studies.
Common questions
- Are there clinical trials studying Relatlimab?
- Yes. Clin2 currently lists 30 recruiting studies that include Relatlimab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Relatlimab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Relatlimab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Relatlimab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.